May 3, 2017          This is Finn Hawkins and Katherine McCauley. Credit: Jackie    Ricciardi    
      Human lungs, like all organs, begin their existence as clumps      of undifferentiated stem cells. But in a matter of months,      the cells get organized. They gather together, branch and      bud, some forming airways and others alveoli, the delicate      sacs where our bodies exchange oxygen for carbon dioxide. The      end result, ideally: two healthy, breathing lungs.    
    For years, scientists who study lung diseases like cystic fibrosis have tried to track this    process in detail, from start to finish, in the hope that    understanding how lungs form normally may help explain how    things go wrong. Now, scientists at Boston University's Center    for Regenerative Medicine (CReM) have announced two major    findings that further our understanding of this process: the    ability to grow and purify the earliest lung progenitors that    emerge from human stem cells, and the ability to differentiate    these cells into tiny "bronchospheres" that model    cystic fibrosis. Researchers hope that the results, published    separately in the Journal of Clinical Investigation and    Cell Stem Cell, will lead to new, "personalized    medicine" approaches to treating lung disease.  
    "Sorting these cells to purity is really difficult and    important," says Darrell Kotton, director of CReM and co-senior    author of both papers, with Brian Davis of UTHealth at the    University of Texas. "It's the first step in trying to predict    how an individual might respond to existing treatments or new    drugs."  
    "There's a long list of lung diseases for which there are no    treatments other than a lung transplant," added Kotton, whose    work is funded by the National Institutes of Health (NIH), the    Cystic Fibrosis Foundation, and the Massachusetts Life Sciences    Center. "It's critically important to develop new tools for    understanding these diseases."  
    CReM scientists work with induced pluripotent stem cells, or iPSCs,    which were discovered by Shinya Yamanaka in 2006. Yamanaka    figured out how to take an adult cell in the human bodylike a    blood cell or skin celland "reprogram" it into a stem cell    with the ability to grow into any organ. In recent years,    several groups of scientists have grown lung cells from human    iPSCs, but the recipes aren't perfectthe resulting lung cells    grow amidst a jumble of liver cells, intestinal cells, and    other tissues.  
    "That's a big issue," says Finn Hawkins, a BU School of    Medicine (MED) assistant professor of medicine and part of the    CReM team. Hawkins is co-first author on the Journal of Clinical    Investigation paper, along with Philipp Kramer,    formerly of UTHealth. "If you want to use these cells to study    the lung, you need to get rid of those others."  
    First, Hawkins needed a way to identify the lung cells.    Previous work by Kotton and other CReM scientists demonstrated    that mouse stem cells express a gene called Nkx2-1 at the "fate    decision"the moment they turn into lung cells. "That's the    first gene that comes on that says, 'I'm a lung cell,'" says    Hawkins. Kotton built a reporter gene that glowed green when    the stem cells first expressed Nkx2-1, and Hawkins engineered    the same gene into human cells. Now, he could easily spot and purify    the glowing green lung cells.  
    Using a flow cytometer, Hawkins and his colleagues separated    the green cells out from the mix, then grew them in a matrix.    The result: tiny green spheres about half a millimeter across,    "a population of pure, early lung cells," says Hawkins. The    team calls the tiny spheres "organoids," simplified and    miniaturized versions of an organ, containing key types of lung    cells. The organoids are tools, and they serve at least two    important purposes. First, they allow scientists to study, in    detail, a critical juncture in human lung development about    which very little is known. "We discovered that many of the    genes that control lung development in other species, such as    mice, are also expressed in these human cells," says Hawkins.  
    The organoids serve another purpose, as well: scientists can    grow them into more mature, specific cell typeslike airway    cells or alveolar cellsthat are critical for lung function.    "Now we can actually start looking at disease," says Hawkins.    That's where Katherine McCauley (MED'17), a fifth-year PhD    candidate at CReM, enters the picture.  
    McCauley's interest is cystic fibrosis, a disease caused by    mutations in a single gene, CFTR. The mutation causes a    person's lungs to produce a thick, viscous mucus that leads to    infection, inflammation, and, eventually, lung failure. For    many patients, there is no cure.  
    McCauley, looking at the earliest stages of the disease, wanted    to take Hawkins' purified lung cells to the next step and    figure out how they became airway cells. Through many    painstaking experiments, she zeroed in on a signaling pathway    called Wnt, known to be important in mouse lung development. By    turning the pathway off, she guided the immature lung cells into becoming airway cells. Then, she grew them into tiny balls    of cells, which she called "bronchospheres."  
    Like Hawkins' organoids, the bronchospheres don't act like a    bronchus; they are simply a collection of specific cells. But    their specificity makes them exquisitely useful. "We wanted to    see if we could use these to study airway diseases," says    McCauley. "That's one of the big goals: to engineer these cells    from patients and then use them to study those patients'    diseases."  
    As a proof of concept, McCauley obtained two cell lines from a    patient with cystic fibrosis, one in which the CFTR mutation    that caused the disease had been corrected, and one in which it    hadn't, and grew them into bronchospheres. To see if her recipe    worked, she ran a test, applying a drug that should cause    spheres made of normal, functioning cells to fill with fluid.    It worked: the "fixed" bronchospheres began to swell, while the    cystic fibrosis spheres didn't react. "The cool part is that we    measured this using high-throughput microscopy, and then we    calculated the change in area with time," says McCauley, who    published these results in     Cell Stem Cell and is lead author on the study. "So    now we can evaluate CFTR function in a quantitative way."  
    The next step, says McCauley, is to improve the test, and scale    it up, and create similar tests for other lung diseases. "The end goal is to take cells    from a patient, and then screen different combinations of    drugs," she says. "The idea that we could take a patient's    cells and test not twenty, but hundreds or thousands of drugs,    and actually understand how the patient was going to respond    before we even give them the treatment, is just an incredible    idea."  
     Explore further:    New    study makes strides towards generating lung tissue  
        Using Induced pluripotent stem cells (iPSCs), researchers        have for the first time profiled the complete genetic        programs of early lung progenitors identifying genes that        control lung formation and have created mini-lung organoids        ...      
        Researchers have developed a new approach for growing and        studying cells they hope one day will lead to curing lung        diseases such as cystic fibrosis through "personalized        medicine."      
        Researchers have discovered a new efficient way to generate        thyroid cells, known as thyrocytes, using genetically        modified embryonic stem cells.      
        A new study has found that stem cell therapy can reduce        lung inflammation in an animal model of chronic obstructive        pulmonary disease (COPD) and cystic fibrosis. Although,        still at a pre-clinical stage, these findings have ...      
        Researchers at Boston University School of Medicine (BUSM)        and Boston Medical Center (BMC) have derived a population        of pure lung and thyroid progenitor cells in vitro that        successfully mimic the developmental milestones ...      
        Researchers at the University of Toronto and the Hospital        for Sick Children (SickKids) are paving the way towards        individualized medicine for patients with cystic        fibrosis.      
        Exosomes isolated from very obese patients behave very        differently than those derived from lean patients and may        be key players in heightening youths' likelihood of        developing atherosclerosis - which, in turn, places them        ...      
        A new Yale-led study detailing how blood vessels develop        could lead to novel treatments of cardiovascular diseases        as well as cancer.      
        Research at the University of Illinois at Urbana-Champaign        has provided the first evidence that viruses and hosts        share highly similar regulatory sequences in their        promotersthe initiation sequences of human genes that ...      
        The puzzle of how the brain regulates blood flow to prevent        it from being flooded and then starved every time the heart        beats has been solved with the help of engineering.      
        Over the decades, scientists have repeatedly shown that        patients with increased levels of the hormone insulin in        their blood can experience increased risks of cancer.        Surprisingly, however, Joslin Diabetes Center researchers        ...      
        New research has unravelled the mystery of how        mitochondriathe energy generators within cellscan        withstand attacks on their DNA from rogue molecules.      
      Please sign      in to add a comment. Registration is free, and takes less      than a minute. Read more    
See original here:
Scientists turn human induced pluripotent stem cells into lung cells - Medical Xpress